[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"primary-progressive-multiple-sclerosis-ppms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:primary-progressive-multiple-sclerosis-ppms":59},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":5},"100452900",false,"NCT05177523","Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis","INsIDER: Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis","INsIDER","Inclusion Criteria for patients:\n\n* Patients may be diagnosed with:\n\n  1. active RRMS (n=100): Relapsing-remitting course and \\> 1 clinical relapse and\u002For signs of MRI activity (\\> 1 Gd enhancing lesion) during the last year before study enrollment.\n  2. non-active PMS (n=100): Progressive course (PPMS or SPMS) and no clinical relapses and\u002For signs of MRI activity during the last year before study enrollment.\n* Age 18-80 years old\n* No other neurological or psychiatric disorder\n\nInclusion criteria for healthy controls:\n\n* Age 18-80 years old\n* No other neurological or psychiatric disorder\n\nExclusion Criteria for patients and healthy controls:\n\n* Pregnancy\n* Contraindication to MRI (eg, claustrophobia, metallic implants, pacemaker etc).\n* Inability to give consent",true,"ALL","18 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","This project is to:\n\n1. Quantify differences in axonal integrity and organization in aMS versus naPMS patients.\n2. Quantify changes in axonal integrity and organization in aMS versus naPMS patients over a two-year period.\n3. Validate the combination of imaging parameters that best differentiate aMS versus naPMS patients using histopathology.",[26,27,28,29],"Multiple Sclerosis (MS)","Relapsing-remitting Multiple Sclerosis (RRMS)","Secondary-progressive Multiple Sclerosis (SPMS)","Primary Progressive Multiple Sclerosis (PPMS)",[31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"axonal damage","axonal demyelination","axonal degeneration","axonal loss","axonal disorganization","axonal repair","axonal remyelination","axonal reorganization","Advanced MRI (aMRI)","Neurite Orientation Dispersion and Density Imaging (NODDI)","Diffusion Kurtosis (DK)","Magnetization Transfer Imaging (MTI)","Multi-echo Susceptibility-Based imaging (SBI)","Myelin Water Imaging (MWI)","T1 relaxometry (quantitative T1, qT1)","machine learning technique","RECRUITING","2024-12-13",{"date":50,"type":51},"2024-12-16","ACTUAL",{"date":53,"type":51},"2018-09-04",{"date":55,"type":22},"2028-12",{"name":57,"class":58},"University Hospital, Basel, Switzerland","OTHER",""]